职称：研究员

学历：博士

电话：0591-22867972

电子邮件：cyuan@fzu.edu.cn

研究方向：化学生物学、生物化学与分子生物学

工作经历：

1. 2016.6－      福州大学生物科学与工程学院    

2. 2010.6－2011.6   哈佛大学医学院（访问学者）                

3. 2003.7－2016.6   中国科学院福建物质结构研究所  

教育经历：

4. 2005.3－2008.7   中国科学院福建物质结构研究所生物化学与分子生物学 博士

5. 2000.9－2003.7   福建师范大学生物化学与分子生物学 硕士

教学简介：

本科生课程《蛋白质化学与工程》，研究生课程《蛋白质结构与现代药物开发》。指导学生获得福建省研究生优秀学位论文。

科研简介：

主要从事蛋白的结构和功能研究，并基于结构进行多肽和蛋白类药物的改造和评价。目前已发表SCI论文九十余篇，先后主持国家自然科学基金面上项目及福建省自然科学基金重点项目等。主要研究领域包括：

1、肿瘤迁移相关蛋白的结构和功能研究：几乎90％癌症病人的死亡是由于癌细胞的转移性扩散引起。目前针对原发性肿瘤的治疗卓有成效，但靶向肿瘤转移方面的进展却不尽人意。我们主要针对肿瘤迁移相关的一些蛋白如尿激酶受体系统和多种丝氨酸蛋白酶，及其与抑制剂的复合物进行X-射线晶体结构研究，并针对这些结构指导抑制剂的改造，以发展高效特异的肿瘤治疗药物。

2、血栓形成相关蛋白的结构和功能研究：人体保持血液处于正常流动状态，主要依赖于凝血系统和纤溶系统处于一个动态平衡。病理条件下两个系统的功能异常将导致出血或血栓形成。我们针对凝血和纤溶相关的一些蛋白如纤溶酶原激活物tPA、多种凝血因子及它们的调控蛋白PDI进行结构和功能的研究，并基于这些结构进行抑制剂的设计和改造，以发展高效且无出血副作用的溶栓和抗血栓形成药物。

3、光动力抗肿瘤和抗菌研究：光敏剂在特定波长的光激发下可产生具有生物毒性的单线态氧或者自由基，进而杀死细胞或微生物，可用于抗肿瘤和抗菌方面的治疗。传统的光敏剂存在靶向性差，水溶性不佳等问题。我们对光敏剂进行一系列的修饰和包裹，发展高靶向性光敏剂，用于抗肿瘤和耐药菌的治疗。

主持的科研项目：

6. 福建省自然科学基金重点项目，基于结构的溶栓剂改造及联合用药策略优化（2022J02017），2022.08-2025.08

7. 国家自然科学基金面上项目，内吞性胶原蛋白受体Endo180的结构研究（31570745），2016.01-2019.12

8. 国家自然科学基金面上项目，肝细胞生长因子激活物抑制剂1的结构研究（31170707），2012.1-2015.12

9. 国家自然科学基金面上项目，基质降解相关蛋白的结构研究（30770429），2008.1-2010.12

近五年代表性论文：（^*为通讯作者）

10. Li HL, Qu YH, Guo ZZ, Chen D, Jiang LG, Xu P, Huang MD*, Yuan C*. Dual modified ferritin nanocages for tumor-targeted and microenvironment-responsive drug delivery. International Journal of Biological Macromolecules 2025, 303.

11. Zhang DP, Du LY, Gao HS, Yuan C*, Lin ZH*. Structural insight into the Csx1-Crn2 fusion self-limiting ribonuclease of type III CRISPR system. Nucleic Acids Research 2024, 52(14), 8419-8430.

12. Yan W, Li HL, Ning JM, Huang SH, Jiang LG, Xu P, Huang MD*, Yuan C*. Engineered protein cages with enhanced extracellular drug release for elevated antitumor efficacy. International Journal of Biological Macromolecules 2024, 267.

13. Xu YY, Hu YP, Wu GQ, Niu LL, Fang C, Li YK, Jiang LG, Yuan C*, Huang MD*. Specific inhibition on PAI-1 reduces the dose of Alteplase for ischemic stroke treatment. International Journal of Biological Macromolecules 2024, 257.

14. Wang GD, Li JH, Zhang W, Jiang LB, Mai YH, Chen JY, Deng LA, Chen LY, Lin YX, Li XM, Zou HS, Xu P, Jiang LG, Yuan C*, Huang MD*. A class of photosensitizer highly effective to control bacterial infection in plants even on rainy days with dim light. Dyes and Pigments 2024, 225.

15. Li JH, Wang GD, Mai YH, Zhang W, Zhao HL, Zhou Y, Chen LY, Lin YX, Jiang LG, Xu P, Zhou XL*, Yuan C*, Huang MD*. Lysosome-localization and tumor-targeting of novel photosensitizers enhance the ablation of cancer. Journal of Photochemistry and Photobiology B-Biology 2024, 261.

16. Chen SL, Fang SD, Zhou Y, Huang ZW, Yu SJ, Chen D, Wang ZY, Xu YY, Liu PW, Li YK, Lin W, Jiang LG, Yuan C*, Huang MD*. A low bleeding risk thrombolytic agent: citPA5. Cardiovascular Research 2024, 120(10), 1191-1201.

17. Xu YY, Chen D, Liu PW, Hu YP, Peng SZ, Chen SL, Li YK, Lin W, Jiang LG, Yuan C*, Huang MD*. A triple fusion tissue-type plasminogen activator (TriF-AtPA) enhanced thrombolysis in carotid embolism-induced stroke model. International Journal of Pharmaceutics 2023, 637.

18. Liu DF, Jiang LG, Chen JC, Chen Z, Yuan C*, Lin DH*, Huang MD*. Monomer and Oligomer Transition of Zinc Phthalocyanine Is Key for Photobleaching in Photodynamic Therapy. Molecules 2023, 28(12).

19. Liao XY, Ji PP, Chi KX, Chen XY, Zhou Y, Chen SL, Cheng Y, Flaumenhaft R, Yuan C*, Huang MD*. Enhanced inhibition of protein disulfide isomerase and anti-thrombotic activity of a rutin derivative: rutin:Zn complex. Rsc Advances 2023, 13(17), 11464-11471.

20. Li HL, Wang ZY, Yu SJ, Chen SL, Zhou Y, Qu YH, Xu P, Jiang LG, Yuan C*, Huang MD*. Albumin-based drug carrier targeting urokinase receptor for cancer therapy. International Journal of Pharmaceutics 2023, 634.

21. Yu SJ, Sui YQ, Wang JW, Li YD, Li HL, Cao YP, Chen LQ, Jiang LG, Yuan C*, Huang MD*. Crystal structure and cellular functions of uPAR dimer. Nature Communications 2022, 13(1).

22. Wang GD, Yang L, Jiang LB, Chen JY, Jing Q, Mai YH, Deng LA, Lin YX, Chen LY, Chen Z, Xu P, Jiang LG, Yuan C*, Huang MD*. A new class of quaternary ammonium compounds as potent and environmental friendly disinfectants. Journal of Cleaner Production 2022, 379.

23. Liao XY, Zhuang XX, Liang CH, Li JY, Flaumenhaft R, Yuan C*, Huang MD*. Flavonoids as Protein Disulfide Isomerase Inhibitors: Key Molecular and Structural Features for the Interaction. Journal of Agricultural and Food Chemistry 2022, 70(14), 4475-4483.

24. Liang CH, Flaumenhaft R, Yuan C*, Huang MD*. Vascular thiol isomerases: Structures, regulatory mechanisms, and inhibitor development. Drug Discovery Today 2022, 27(2), 626-635.

25. Liang CH, Cai MQ, Xu YY, Fu W, Wu JH, Liu YR, Liao XY, Ning JM, Li JY*, Huang MD*, Yuan C*. Identification of Antithrombotic Natural Products Targeting the Major Substrate Binding Pocket of Protein Disulfide Isomerase. Journal of Natural Products 2022, 85(5), 1332-1339.

26. Huang ZW, Lin HJ, Yu SJ, Li HL, Zhou Y, Cheng Y, Chen SL, Yuan C*, Huang MD*. A versatile insertion point on albumin to accommodate peptides and maintain their activities. International Journal of Biological Macromolecules 2022, 205, 49-54.

27. Chen SL#, Yuan C#, Jiang LG, Luo ZP*, Huang MD*. Crystallographic analysis of interaction between cisplatin and human serum albumin: Effect of fatty acid. International Journal of Biological Macromolecules 2022, 216, 172-178.

28. Chen SL, Chen D, Liu YR, Xu YY, Lin HJ, Cheng Y, Li JY, Meng C, Liang ML, Yuan C*, Huang MD*. Enhanced clot lysis by a single point mutation in a reteplase variant. British Journal of Haematology 2022, 196(4), 1076-1085.

29. Chen D, Liu YR, Liu PW, Zhou Y, Jiang LG, Yuan C*, Huang MD*. Orally delivered rutin in lipid-based nano-formulation exerts strong antithrombotic effects by protein disulfide isomerase inhibition. Drug Delivery 2022, 29(1), 1824-1835.

30. Zhang D, Chen JY, Jing Q, Chen Z, Ullah A, Jiang LG, Zheng K, Yuan C*, Huang MD*. Development of a Potent Antimicrobial Peptide With Photodynamic Activity. Frontiers in Microbiology 2021, 12.

31. Yuan C, Guo ZZ, Yu SJ, Jiang LG*, Huang MD*. Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners. Drug Discovery Today 2021, 26(4), 1076-1085.

32. Yu SJ, Sun GH, Sui YQ, Li HL, Mai YH, Wang GD, Zhang N, Bi YH, Gao GF, Xu P, Jiang LG, Yuan C*, Yang Y*, Huang MD*. Potent inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 by photosensitizers compounds. Dyes and Pigments 2021, 194.

33. Li LL, Huang MX, Shen JS, Wang Y, Wang R, Yuan C*, Jiang LG, Huang MD. Serum Levels of Soluble Platelet Endothelial Cell Adhesion Molecule 1 in COVID-19 Patients Are Associated With Disease Severity. Journal of Infectious Diseases 2021, 223(1), 178-179.

34. Jiang LG, Yuan C*, Huang MD*. A general strategy to inhibit serine protease by targeting its autolysis loop. Faseb Journal 2021, 35(2).

35. Jiang LB, Jiang YB, Li LL, Zheng K, Yu SJ, Li JY, Yuan C*, Huang MD*. A supramolecular nanocarrier for efficient cancer imaging and therapy by targeting at matriptase. Journal of Controlled Release 2021, 334, 153-163.

36. 许燕艳; 陈珊莉; 陈丹; 彭双周; 程媛; 李金宇; 李永坤; 江龙光; 袁彩*; 黄明东*. 缺血性脑卒中溶栓药物研究进展. 生物工程学报 2020, 36 (10), 2029-2039.

37. 梁程辉; 陈丹; 廖馨源; 江龙光; 袁彩*; 黄明东*. 蛋白质二硫键异构酶的结构及抑制剂研究进展. 生物化学与生物物理进展 2020, 47 (07), 595-606.

38. Li LL, Chen D, Zheng K, Jiang LB, Dai T, Yang L, Jiang LG, Chen Z, Yuan C*, Huang MD*. Enhanced Antitumor Efficacy and Imaging Application of Photosensitizer-Formulated Paclitaxel. Acs Applied Materials & Interfaces 2020, 12(4), 4221-4230.

39. Jiang YB, Lin L*, Chen SL, Jiang LG, Kriegbaum MC, Grdsvoll H, Hansen LV, Li JY, Ploug M, Yuan C*, Huang MD*. Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/α-neurotoxin Domain. International Journal of Biological Sciences 2020, 16(6), 981-993.

40. Jiang LB, Liu YR, Xu XY, Su D, Zou HS, Liu JY, Yuan C*, Huang MD*. Inhibition of the Citrus Canker Pathogen Using a Photosensitizer Assisted by Sunlight Irradiation. Frontiers in Microbiology 2020, 11.

其他

研究生招生专业：生物医学工程、生物工程、生物技术与工程；欢迎有志从事科研工作的硕士生报考我们课题组。

课题组介绍：http://fmerc.fzu.edu.cn/html/rcdw/hmdktz/1.html